Shri ThanedarSell
Coherus BioSciences, Inc. · Transaction Jan 23, 2023 · Filed Feb 9, 2023 · $15,001 to $50,000
NASDAQ NMS - GLOBAL MARKET · CHRS
+7.90% · +$0.0800 · Vol 2.1M
Market closed · last close 4:00 PM ET · price as of 19:59:21 ET
Coherus Oncology Inc
Biotechnology
$1.09
Follow $CHRS
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $CHRS by emailVeridion Score
BETAHIGH CONF · 6 of 6 factors measuredThu Oct 8 · market closed · Markets closed · resumes Fri 9:30 ET · CHRS
MethodologyCHRS
Coherus Oncology Inc
Thu Oct 8 · market closed · Markets closed · resumes Fri 9:30 ET
Middle range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
54/ 100
Veridion Score
Middle range · HIGH confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6 of 6 factors measured · Thu Oct 8 · market closed · Markets closed · resumes Fri 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is CHRS moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Coherus Oncology Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Listed since
2014
Employees
144
Country
US
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$1.01
Day high
$1.07
Day low
$0.9740
Previous close
$1.01
52W high
$2.51
-56.58% from high
52W low
$0.9740
8% of range
Market cap
$156M
P/E
0.93×
EPS
$-1.0326
Beta
0.78
Shares out
154.5M
Volume
2.1M
1.58× rel vol
Avg volume
1.4M
VWAP
$1.03
Price history computed in-house
1W
-6.05%
1M
-17.44%
3M
-29.23%
1Y
-40.12%
YTD
-23.25%
SMA 50 $1.29 · below
SMA 200 $1.57 · below
52W position 8%
CHRS overview
Related filings and maps
Public disclosures
Congress activity in CHRS
1 filers · 0 buys · 1 sells (0 labeled S (partial)) · Jan 23, 2023 to Jan 23, 2023 · House 1 / Senate 0
All available history · Latest 1 of 1 lines · Read 2026-10-09T01:13:43.420Z
Official filing ↗
Federal contracts
CHRS contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for CHRS in this window.
Lobbying spend
CHRS lobbying filings, year to date.
Registered lobbying filings matched to Coherus Oncology Inc.
$375.0K
Refresh interval: 12hSource: LDA disclosure filings
Health Issues
Government IssuesHealth Issues
Medicare/Medicaid
Filing
$95.0K
COHERUS BIOSCIENCES INC.
COHERUS BIOSCIENCES
Jul 28, 2026
Filing
$80.0K
COHERUS BIOSCIENCES INC.
COHERUS BIOSCIENCES, INC.
May 18, 2026
Filing
$80.0K
COHERUS BIOSCIENCES INC.
COHERUS BIOSCIENCES, INC.
Mar 9, 2026
Analyst ratings
Sovereign unlock shows live analyst consensus for CHRS.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.